Mnder et al. 2002. Immumophilins and HIV-1 Infection, Arch. Virol., vol. 147, pp. 1531-1542.* |
Gottschall, P.E., 1996, B-amyloid Induction of Gelatinase B Secretion in Cultered Microglia: Inhibition by Dexamethasone. Neuroreport 7(18):30-77-3080.* |
Milad et al. 1995. Interaction of the Progesterone Receptor with Binding Proteins for FK506 and Cyclosporin A. Molecular Endocrinology 9: 838-847.* |
T. Kato, Nippon Shishubyo Gakkai Kaisha, vol. 37, No. 2, pp. 211-223, “Effect of immunosuppressant Drug (FK 506 and Ciclosporin) on Gingival Fibroblasts”, 1995. |
M. J. Tocci, et al., The Journal of Immunology, vol. 143, No. 2, pp. 718-726, “The Immunosuppressant FK 506 Selectviely Inhibits Expression of Early T Cell Activation Genes”, Jul. 15, 1989. |
C. Arita, et al., Clin. Exp. Immunol., vol. 82, No. 3, pp. 456-461, “Inhibition by FK 506OF Established Lesions of Collagen-Induced Arthritis in Rats”, 1990. |
K. Koch, et al., Inflamation Res., vol. 44, Supplement 2, pp. S183-S184, “CP-123,369: A Potent, Orally Active Immunosuppressive Agent”, 1995. |
E. Sujiyama, et al., The Journal of Rheumatology, vol. 21, No. 9, pp. 1597-1601, “FK506, An Immunosuppressant, Partially Inhibits Interleukin 6 Production by Adherent Rheumatoid Synovial Cells”, 1994. |
R. J. Griffiths, et al., Agents Actions, vol. 36, No. 1-2, pp. 146-151, “Characterisation of Passively Transferred Antigen Arthritis Induced by Methylated Bovine Serum Albumin in the Rat: Effect of FK 506 on Arthritis Development”, 1992. |
A. Zeniya, et al., Journal of Gastroenterology, vol. 29, No. 3, pp. 383-384, “Anti-Ulcer Effect of FK 506, Immunosuppressive Agent, In Rats”, 1994. |
T. Karashima, et al., Journal of Dermatological Science, vol. 12, No. 3, pp. 246-254, “FK 506 and Cyclosporin A Inhibit Growth Factor-Stimulated Human Keratinocyte Proliferation by Blocking Cells in the G0/G1 Phases of the Cell Cycle”, 1996. |
U. Mrowietz, et al., British Journal of Dermatology, vol. 139, No. 6, pp. 992-996, “The Novel Ascomycin Derivative SDZ 981 is Effective for Psoriasis when used Topically Under Occlusion”, 1998. |
S. P. Butcher, et al., The Journal of Neuroscience, vol. 17, No. 18, pp. 6939-6946, “Neuroprotective Actions of FK506 in Experimental Stroke: In Vivo Evidence Against An Antiexcitotoxic Mechanism”, Sep. 15, 1997. |
H. Inaba, et al., Sei Mariana-ika Diagaku Zasshi, vol. 26, No. 5, pp. 555-563, “Effect of Indomethacin and Tacrolimus Hydrate on the Healing Process of Experimental Gastic Ulcers of Rats Created By Mucosal Resection: Course of Changes in the Interleukin-1β (Il-1β) Expression”, 1998. |
W. J. Sandborn, The American Journal of Gastroenterology, vol. 92, No. 5, pp. 876-879, “Preliminary Report on the Use of Oral Tacrolimus (FK506) in the Treatment of Complicated Proximal Small Bowel and Fistulizing Crohn's Desease”, 1997. |
Y. Hisanaga, et al., Alimentary Phamacology & Therapeutics, vol. 10, No. 10, pp. 933-940, “Implicaiton of Nitric Oxide Synthase Activity in the Genesis of Water Immersion Stress-Induced Gastric Lesions in Rats: The Protective Effects of FK506”, 1996. |